These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 34514186)

  • 1. Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients.
    Liu EC; Lee JH; Loo A; Mazur S; Sultan S; Aull M; Lee JB; Muthukumar T; Hartono C
    Kidney Int Rep; 2021 Nov; 6(11):2900-2902. PubMed ID: 34514186
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
    Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
    Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19.
    Markovitz NH; Pedersen E; Sachs DL; Bresler SC
    JAAD Case Rep; 2022 Sep; 27():156-158. PubMed ID: 35845347
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
    Luitel P; Vais D; Gidron A
    Open Forum Infect Dis; 2021 Aug; 8(8):ofab335. PubMed ID: 34405092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan.
    Osugi Y; Iwata H; Imai Y; Kobayashi D; Hirashima R
    Cureus; 2022 Feb; 14(2):e21882. PubMed ID: 35273850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Casirivimab/Imdevimab in Kidney Transplant Recipients Admitted with Mild-to-Moderate COVID-19: A Case Series.
    Rajmane SS; Patil AA; Dash CS; Bahadur MM; Shingare A; Deshpande RV
    Indian J Nephrol; 2023; 33(5):371-372. PubMed ID: 37881734
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Effectiveness of REGN-COV2 in Patients with COVID-19 in Japan: A Retrospective Cohort Study with a Bayesian Inference.
    Amano N; Iwata K; Iwata S
    Infect Chemother; 2021 Dec; 53(4):767-775. PubMed ID: 34979607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Cohort Study of Indian Centers on Reoccurring SARS-CoV-2 Infections in Kidney Transplant Recipients.
    Kute VB; Hegde U; Das P; Sharma A; Bahadur MM; Sil K; Guleria S; Varma PP; Jamale T; Meshram HS
    Exp Clin Transplant; 2021 Oct; 19(10):1023-1031. PubMed ID: 34498549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.
    Heustess AM; Allard MA; Thompson DK; Fasinu PS
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34071185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19.
    Tseng HT; Wu XC; Huang CY; Shih CM; Lin YW; Lin FY
    Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
    Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
    J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients.
    Nailescu C; Khalid M; Wilson AC; Amanat F; Arregui S; Canas J; Hooks J; Krammer F; Schwaderer AL; Hains DS
    Front Pediatr; 2020; 8():601327. PubMed ID: 33194930
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of disease severity and outcome of hospitalized renal transplant recipients with COVID-19 infection: a systematic review of a globally representative sample.
    Hasan I; Rashid T; Suliman S; Amer H; Chirila RM; Mai ML; Jarmi T; Khouzam S; Franco PM; Heilig CW; Wadei HM
    Rom J Intern Med; 2021 Mar; 59(1):10-42. PubMed ID: 33155999
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
    Chiarucci M; Paolasini S; Isidori A; Guiducci B; Loscocco F; Capalbo M; Visani G
    Front Oncol; 2021; 11():737300. PubMed ID: 34552880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erratum for Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan.
    Katsuo C; Kubota K; Tanaka K; Kurita Y; Nakajima A
    Intern Med; 2023; 62(17):2595. PubMed ID: 37661419
    [No Abstract]   [Full Text] [Related]  

  • 17. Casirivimab and imdevimab for COVID-19.
    Aust Prescr; 2022 Apr; 45(2):58-59. PubMed ID: 35592369
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV2 Infection in Hematopoietic Stem Cell Transplant recipients: A Case Series from a Tertiary Cancer Centre in India.
    Rajendra A; Gokarn A; Mirgh S; Ravind R; Singh A; Goli VB; Punatar S; Chichra A; Tembhare P; Patkar N; Bhat V; Chavan P; Trivedi B; Joshi A; Khattry N
    Indian J Hematol Blood Transfus; 2021 Oct; 37(4):699-701. PubMed ID: 34007125
    [No Abstract]   [Full Text] [Related]  

  • 19. A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
    Ahearn AJ; Thin Maw T; Mehta R; Emamaullee J; Kim J; Blodget E; Kahn J; Sher L; Genyk Y
    Transplantation; 2022 Feb; 106(2):e153-e157. PubMed ID: 34519680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience.
    Chilimuri S; Mantri N; Gurjar H; Youthjug KA; Sun H; Gongati S; Zahid M; Ronderos DM; De La Cruz A; Varanasi P; Shin D; Nayudu SK
    J Natl Med Assoc; 2022 Jan; 113(6):701-705. PubMed ID: 34521513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.